Top March Stocks to Buy in 2011

Coca-Cola (KO, news) is gaining attention as an undervalued blue chip that's ideally positioned to help many investors get where they want to go as the bull market enters its third year.


Jim Cramer's Mad Money: Watch TV, Get Rich

As with other mega-cap stocks, Coca-Cola shares are cheaper than their average price over the last decade -- investors are paying 13 times per-share earnings over the past 12 months, a discount from Coca-Cola's 10-year average P/E ratio of 25.
Mad Money: Back to Basics


The Dow component is a reliable source of dividends -- it has raised its payout for 49 consecutive years. The most recent increase was in February, when directors approved a 6.8% increase to 47 cents a share.


Mad Money: Back to Basics II: Invest Like a Pro







Invest in Coca-Cola or PepsiCo?

.

Dividends are a big reason Warren Buffett is so bullish on Coca-Cola. His investment vehicle, Berkshire Hathaway (BRK.B, news), is Coca-Cola's largest shareholder, with 8.6% of the company's stock. Berkshire last purchased Coca-Cola shares in 1995.



•What's ahead for the stock market
Mad Money Bull Keychain
Investors sat up and took notice this year when Buffett, in his much-anticipated annual letter to Berkshire shareholders, said he expects Coca-Cola dividends to double within a decade. If Buffett's right, the Atlanta company's dividend yield could jump to above 5.5% in 10 years, from 2.8% today.





Coca-Cola chief on growth plans



View more MSN videosGo to CNBC







"By the end of that period, I wouldn't be surprised to see our share of Coke's annual earnings exceed 100% of what we paid for the investment," Buffett wrote in the Feb. 26 letter. "Time is the friend of the wonderful business."



Coca-Cola appears on a daily ranking created using StockScouter, an MSN Money tool that identifies stocks with strong growth prospects in the near term. All stocks with Scouter ratings of 8, 9 or 10 are considered for the list, which is then shortened to exclude stocks with a trading volume below 50,000 shares a day. The remaining stocks are ranked on the basis of market capitalization, sector membership and whether they are growth or value stocks.
Perfect Solutions Digital Coin Counting Money Jar


With operations in more than 200 countries, Coca-Cola is the world's biggest soft-drink company. It owns four of the top five soft-drink brands (Coca-Cola, Diet Coke, Fanta, and Sprite). Other brands include Minute Maid juices, Dasani water and Honest Tea.


Mad Money w/ Jim Cramer Back To Basics II: Invest Like A Pro
Global sales rose in the fourth quarter despite a soft economy, the company said, with emerging markets like Brazil and India providing the fastest growth. It's also making a big push into Africa, where Coke is the dominant brand and a middle class is just emerging.



Coca-Cola also took market share from rival PepsiCo (PEP, news) in North America in the fourth quarter. Wall Street has been more bullish on Coca-Cola than on Pepsi in recent quarters because of Coca-Cola's strong global brands and its absence of snack foods, which tend to have lower profit margins and are more susceptible to rising commodity prices.







.

Of 15 analysts covering the company, 11 rate Coca-Cola a "strong buy," three rate it a "moderate buy" and one has a "hold" rating.



The stock has a StockScouter rating of 9, meaning it is expected to significantly outperform the market over the next six months with very low risk by MSN.com/money

top 10


Company Sector Friday's close Forward P/E Scouter score

Chesapeake Energy (CHK, news) Oil and natural gas $32.81 10.9 10

Gap (GAP, news) Apparel $21.97 10.4 10

Coca-Cola (KO, news) Soft drinks $64.81 15.1 9

Exxon Mobil (XOM, news) Oil and natural gas $82.12 10.1 9

América Móvil (AMX, news) Telecommunications $55.10 13.1 9

Yamana Gold (AUY, news) Gold mining $12.73 12.3 9

ConocoPhillips (COP, news) Oil and natural gas $76.30 9.7 9

Chevron (CVX, news) Oil and natural gas $99.93 8.5 9

Lowe's (LOW, news) Home improvement $26.94 13.6 9

Macy's (M, news)









 

Best June Stock picks to own ..... (Public, NASDAQ:MNKD) , (Public, NYSE:TXT) ,(Public, NASDAQ:HDNG) .

1. Hardinge Inc. 

(Public, NASDAQ:HDNG) 9.37 a share / target price is 12.00 a share

Hardinge Inc. (Hardinge) is a designer, manufacturer and distributor of machine tools, specializing in precision computer numerically controlled metal-cutting machines. The Company supplies high precision computer controlled metal-cutting turning machines, grinding machines, vertical machining centers, and accessories related to those machines. The Company has manufacturing facilities located in Chemung County, New York; St. Gallen, Switzerland; Biel, Switzerland; Nan Tou City, Taiwan, and Shanghai, People's Republic of China. Canadian Hardinge Machine Tools, Ltd, Hardinge Technology Systems, Inc., Hardinge Holdings GmbH, Hardinge Holdings B.V., Hardinge GmbH, Hardinge Machine Tools, Ltd., Hardinge Machine Tools B.V., L. Kellenberger & Co. AG, Hardinge China, Limited, Hardinge Machine (Shanghai) Co., Ltd., Hardinge Taiwan Precision Machinery Limited, Hardinge Machine Tools B.V. and Taiwan Branch (Hardinge Taiwan). s the 2nd best-performing stock year-to-date in this segment of the market. It has risen 70.36% since the beginning of this year. Its price percentage change is 78.82% for the last 52 weeks.Large Move with Relatively Low Short Interest.Very cheap stock based on Fundamentals. Stock is profitable.Hardinge's products are used in the aerospace, energy, transportation, medical-equipment, automotive, and electronics industries.Very solid company that has been around for a long time. Well-placed company that is trading at a huge discount right now. Probably going to add a decent-sized position, "growth company at value prices with global reach"              Silly Bandz Rock Bandz - 24 Pack

2. 

Textron Inc. 

(Public, NYSE:TXT) 18.96 a share / target price 24.00 

Textron Inc. is a multi-industry company with a global network of aircraft, defense, industrial and finance businesses to provide customers with products and services worldwide. It conducts its business through five operating segments: Cessna, Bell, Textron Systems and Industrial, which represents its manufacturing businesses, and Finance, which represents its finance business. Cessna has five major lines of business: Citation business jets, Caravan single-engine utility turboprops, Cessna single-engine piston aircraft, aftermarket services and lift solutions by CitationAir. Textron Systems provides products to the defense, aerospace and general aviation markets. The Industrial segment includes its Kautex, Greenlee, E-Z-GO and Jacobsen businesses. Its Finance segment consists of Textron Financial Corporation (TFC) and its subsidiaries. In April 2009, the Company completed the sale of HR Textron, an operating unit within its Textron Systems segment, to Woodward Governor Company. When Textron (NYSE:TXT) reported earnings 43 days ago on April 22, 2010, analysts, on average, expected the company to report a loss of $0.01 on sales of $2.4 billion.
The company actually reported EPS of $0.05 on sales of $2.2 billion, beating EPS estimates by $0.06 and missing revenues estimates by $151 million.
Since the company's report, share of Textron have fallen from $24.23 to $18.96, representing a loss of 21.75% in the past 43 days.DEFENSE- DEFENSE- DEFENSE, Strong military contarcts, solid product profile.Great business. Should rebound.
 

3.

MannKind Corporation 

(Public, NASDAQ:MNKD)  5.47 a share / target price 8.50

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The Company’s lead product candidate, AFREZZA (insulin human) Inhalation Powder, is insulin that has completed Phase III clinical trials. AFREZZA utilizes its Technosphere formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. With AFREZZA, the Company loads recombinant human insulin onto the Technosphere particles, however, this technology is not limited to insulin delivery. In March 2009, the Company submitted a new drug application (NDA) to the United Stated Food and Drug Administration (FDA) for AFREZZA. In June 2009, it acquired a quantity of bulk insulin from Pfizer Manufacturing Frankfurt GmbH, a subsidiary of Pfizer Inc. released its most recent earnings statement about a month ago on Friday, April 30th. MannKind Corp. missed expectations with a loss of 40 cents per share---4 cents above the analyst consensus of 44 cents per share.

Now that investors have had plenty of time to assimilate the information and update their positions, it's time to take another look at MannKind Corp.MNKD vs. Its Industry Peers, Simply put, they will get FDA approval following their June meeting and sign a lucrative deal with a big pharma co.

Looking at MNKDcompared to a few of its industry peers, you can see that it is underperforming most of them. This may seem like a bad time for most buyers of MNKD , this is a great time to buy on it low and , make some $$ in the long term play ... FDA approval of Mankind's new insulin dosing technology will be paradigm shift for diabetes patients. The Dreamboat dosing system requires no needles, is very easy to use, uniquely fast acting (effective blood levels in 14 minutes), safe and effective. Multi-bagger stock potential within 1 yr. There is a large market for this product, and the drug will most likely be approved considering previous insulin inhalants were approved. I feel sure there will be a nice bump in price when the FDA approves.

Top March 2009 Stock Picks ! ( Family Dollar Stores & Allos Therapeutics

1. ALTH 5.84 a share Target price 12.00 by 12/09

Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, PDX (pralatrexate) an antifolate is in Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma.
No doubt the market has cost investors a lot of money over the past year and a half. The image of people too afraid to open their 401(k) statements has become cliché. And the common wisdom says that years will pass before those losses are recovered.
But that’s not necessarily the case. Speculating on the right stocks could generate sizable returns, enough to fill some of the holes this recession has poked in your portfolio. That’s one of the reasons that Cramer’s a fan of calculated risk taking. The potential payoff is significant. Speculation’s also a way to keep things interesting. Instead of banking with the usual suspects – maybe Coca-Cola
[KO 40.85 -0.22 (-0.54%) ]
Johnson & Johnson
[JNJ 50.00 -2.44 (-4.65%) ]
[AAPL 89.31 0.12 (+0.13%) ]
– investors can put their money in a small up-and-comer.
So who’s the latest Mad Money Spec Friday pick? Allos Therapeutics
[ALTH 5.64 -0.42 (-6.93%) ]
, a biotech with a $5.64 share price and a market cap of under $500 million. Like all speculation plays, Allos has a catalyst – the probable Food & Drug Administration approval of its cancer drug – that should send the stock higher.
Allos makes an orphan drug called Pralatrexate, or PDX, used to treat peripheral T-cell lymphoma, a fast-spreading cancer that affects white blood cells. Remember an orphan drug is one that treats a very rare condition. So the FDA usually fast tracks approval, the company gets exclusivity rights to the drug, and the sales usually bring in big, big money.
Exclusivity or not, though, PDX is the only treatment for peripheral T-cell lymphoma, so there’s no competition here anyway. President Obama’s plan for Medicare, where the government will negotiate bulk drug prices directly with pharmaceutical companies, could hurt those with similar treatments, but not Allos. And orphan drugs in Europe, where the government already negotiates prices, usually cost the same as, if not more than, those in the U.S. Besides, PDX has been proven to extend patients’ lives. Don’t expect the White House to put a price on that.
On Feb. 4, Allos released data that showed patients who had previously not responded to treatment were responding to PDX, and for longer than expected. The stock popped as a result, and then the market’s decline took ALTH back down. Now ALTH is two points below where it was before the data release, giving investors a great entry point.
Cramer expects Allos to file for final FDA approval by the end of June, which means the drug could be on the market by year’s end. Worst-case scenario, analysts have said, PDX is available to the public by 2010. Sales for the drug could reach as high as $400 million a year, with the chance for even better numbers given PDX’s potential for off-label uses, much like Genentech’s
[DNA 85.55 -1.93 (-2.21%) ]",

Avastin. PDX is more potent than other chemotherapy drugs, so there’s a good chance it could treat other cancers.
Allos makes a great takeover target as well. The company’s a natural fit for any big-time firm with a blood cancer franchise, such as Celgene
got a bid.
Allos reports Tuesday, March 3, so Cramer cautioned against buying before then. The company has no sales yet, so management offer clues as to whether the company’s still on track and possibly even date-release dates on the horizon.
ALTH is a buy at $6, Cramer said, but no more. At $7, the deal doesn’t work. Investors who want in should remember to be patient and use limit orders.



2. FDO 27.44 A SHARE AS OF 3/1 , TARGET PRICE 41.00 by 9/09

Family Dollar Stores, Inc. operates a chain of more than 6,500 general merchandise retail discount stores in 44 states, providing consumers with a selection of merchandise in neighborhood stores. The Company’s merchandise assortment includes consumables, home products, apparel and accessories, and seasonal and electronics. The Company’s products include apparel, food, cleaning and paper products, home decor, beauty and health aids, toys, pet products, automotive products, domestics, seasonal goods and electronics. With a Dividend of .14 a share , is a great buy in this market !In the same boat as Wal-Mart, discount retailers are the some of the few companies showed success in 2008. FDO's stock price gained 36% in 2008.Recession time will prompt more people to go to the dollar stores to $ave MONEY!!!! Due to people needing to cut back, people are going to eventually go from Walmart to Family Dollar as both are in the same merchant category and serve much the same purpose, but Family Dollar seems to undercut Walmart's prices for many items... but does so at a cost: lack of the wide range of products that Walmart does, but from what I've seen, this doesn't effect business one bit.Not bad on debt, fairly good P/E. I'm seeing a lot more "recession fashion" and how-to's on living more cheaply....this company is made for these times.I do about 75% of my regular shopping there (condiments, small food, bread, milk, some clothes.) The stores should do well in hard times.family Dollar Stores . . . need I say more?